The mission of the Day Lab is to take an interdisciplinary approach to identify and develop new and innovative strategies for healthcare.
Our research programme has led to significant research outputs of sustained quality, including UCL's first biomaterial for tissue regeneration granted approval for clinical use by the Medicines and Healthcare Products Regulatory Agency and associated first-in-human phase I/II clinical trial. Our technology is backed by a portfolio of patent families, industry collaborations and licencing agreements.
The core areas of research are: